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ORIGINAL ARTICLE
INTRODUCTION
Several studies in quantify the serum HBsAg
levels have been done. Chen’s et al found a good
correlation between HBsAg and HBV DNA levels in
asymptomatic hepatitis B virus carriers.1 Chan et al
showed that serum HBsAg levels were well
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ABSTRACT
Background: Implication of measuring HBsAg level is still not recognized well. The aim of this study to
recognize the correlation of serum HBsAg level and serum HBV DNA level between in HBeAg positive
patients and HBeAg negative patients.
Method: Quantitative serum HBV DNA were collected retrospectively between January 2006 and
May 2009. We stratified the patients into four groups, that were; HBeAg positive and (a) ALT > 2 x upper
limited normal (UNL) (group A),( b) ALT < 2 x UNL (group B), HBeAg negative and:( a) ALT > 2 x UNL (group
C) (b) ALT < 2 x UNL (group D). We studied the correlation of serum HBsAg and HBV DNA level in each group.
In addition, we also studied the accuracy of HBsAg titers to predict serum HBV DNA levels in each group by
using receiver operating characteristic (ROC) curve analysis.
Results: Eighty nine patients were recruited in this study. Most of them 63 (70%) were male; the mean age of
the patients was 38.49 ± 11.21 years. The number of patients with HBeAg positive and negative were 28 and 61
respectively. Based on the group stratification, the A, B, C and D groups we found 16, 12, 11, 50 respectively.
There was a positive correlation between HBsAg titers and HBV DNA level in HBeAg positive patients but it
was statistically not significant. Similar result was also found in HBeAg negative patients. There were positive
correlation in group A, C, and D but they were not statistically significant. In group B the correlation was
negative (r = -0.40). We found 100% sensitivity and 100% specificity of predicting serum HBV DNA
levels in group A with HBsAg cut-off level of  7.91 IU/mL and baseline serum HBV DNA  cut-off level >
20,000 IU/mL. In group B, C and D the accuracy to predict  serum HBV DNA level were not so good.
Conclusion: There were positive correlation between HBsAg titers and HBV DNA levels in HBeAg positive
and HBeAg negative patients as demonstrated in the three group stratification; however, it was not
significant. There were weak positive correlations between HBsAg level and HBV DNA serum level, for
group A, C and D patients, but again, they were not significant. While in other groups, the correlation
were not so good.
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correlated to the cccDNA and intrahepatic hepatitis B
virus (HBV) DNA.2 Low pret-reatment HBsAg level
is better than HBV DNA for predicting good  response
to peg-interferon and lamivudine treatment in HBeAg
positive patients.2 However, they did not find
correlation between serum HBsAg level and serum
HBV DNA level. Jinlin showed three dynamic
patterns of serum HBsAg levels following treatment
with adevovir and peg-interferon-alfa-2a in HbeAg
positive chronic hepatitis B patient.3 Ozaras et al
concluded that HBsAg quantitative measurement could
be a surrogate marker for viral loading during
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the management of patient with HBeAg positive and
chronic HBV infection.4
In 2004 Krakatau Medika hospital  provided HBsAg
serum examination and the result are expressed as
countable HBsAg titer. When receiving the laboratory
result, the patients frequently asked about
the progression of their disease. We regularly suggested
them to repeat the examination, and if the result of
HBsAg titer increased, the patients worried as it
indicated that they had worse condition. At that time,
we could only provide qualitative result of serum HBV
DNA. Since 2006, we have performed quantitative
measurement of serum HBV DNA, and therefore,
the  quantitative serum levels are available for HBsAg
and HBV DNA.
The cost of HBV DNA examination is relatively
expensive; while the HBsAg examination relatively
cheap and affordable. If HBsAg titer can predict
serum HBV DNA levels, then it would bring a great
value for management of patients. In order to
recognize the correlation of serum HBsAg level and
serum HBV DNA level in HBe positive and HBe
negative patients, retrospectively we search data of
patients with HBsAg positive.
METHOD
Patients who had been examined for their serum
HBV DNA levels quantitatively were recruited recto
spectively between January 2006 and May 2009.
Patients with non countable HBV DNA levels were
excluded. HBsAg titers were noted, as well as
the serum HBeAg, anti HBeAg, and ALT, AST level.
Patients who had laboratory data  between HBsAg
level and HBV DNA level, did not exceed one month
were recruited. AST and ALT serum that time
examined closed to time HBSAg examination were
noted. All examinations were performed at Krakatau
Medika hospital. Patients who were receiving
treatment with interferon or nucleosid analog were
excluded from this study. We stratified the patients into
four groups; group A with HBeAg positive result and
ALT > 2 x UNL; group B with HBeAg positive result
and ALT < 2 x UNL; group C with HBeAg negative
result and ALT > 2 x UNL; and group D with HBeAg
negative result and ALT < 2 x UNL. We studied
the correlation between HBsAg level and serum HBV
DNA level in each groups using Pearson correlation.
We also  evaluated the accuracy of HBsAg titers for
predicting HBV DNA levels in each groups using
receiver operating characteristic (ROC) curve
analysis. For ROC analysis, HBV DNA levels were
divided into HBV DNA > 20,000 IU/mL and HBV
DNA < 20,000 IU/mL in group A and B. In group C
and D, HBV DNA levels were divided into HBV DNA
> 2,000 IU/mL and HBV DNA < 2,000 IU/mL.
Laboratory Assays
We conducted several laboratory assays including
hepatitis B surface antigen assay, serum ALT and AST
assays and serum HBV DNA assay. We used Vidas
HBsAg ultra (Biomerieux, Lyon, France) reagent for
HBsAg assay. The lowest level start from
0.12 ng/mL. Serum HBV-DNA assay; HBV DNA was
extracted by Cobas amplicor HBV monitor test (Roche
diagnostics) according to the manufacturer’s
instructions. HBV DNA was quantified by Cobas
Amplicor HBV monitor test. The range of HBV DNA
detection was from 60 to 3.8 x 104 IU/mL (315 copies/
mL to 2 x 105 copies/mL). Serum ALT assay:  alanine
aminotransferase, Cobas Integra 400, cat. no.
20764957 (Roche diagnostics). The method was
according to the International Federation of Clinical
Chemistry (IFCC) recommendation, but without
pyridoxal-5'-phosphate. We expected ALT values of
31 U/L in female and 41 U/L in male. Serum HBeAg
assay: Vidas HBe/Anti-HBe REF 30 305 (Biomerieux
France) was the reagents used in this study. We
combined the principle of an enzyme immunoassay
method with final fluorescent detection (ELFA)
method.
Statistical Analysis
Statistical tests were performed by SPSS version
13.0. HBV DNA were expressed as logarithmic rather
than the IU/mL for analysis. Data were analyzed by
using Kruskall-Wallis test and Post-Hoc (Mann-
Whitney) test. The Spearman’s correlation coefficient
was tested to demonstrate the correlation between
HBV DNA and HBsAg for four groups stratification.
Statistical significance was defined as a value of
p < 0.05. All statistical measurements were 2-sided
tests.
RESULTS
Eighty nine patients fulfilled the criteria were
recruited. There were 63 (70%) male and 26 (30%)
female. Mean age was 38.49 ± 11.21 years (range
11-60 years). Twenty eight (31.5%) patients were
HBeAg positive, and 61 (68.5%) were HBeAg
negative. Mean value of HBsAg was 22.65 ± 6.5
IU/mL (range 0.74-38.67 IU/mL). The mean value of
HBV DNA was 4.70 ± 1.65 log 10 IU/mL (range 1.86–
7.78 log 10 IU/mL), ALT level median 46.5 (range
11-2,301 IU/mL) (table 1).
 There were 16 (18%), 12 (13.5%), 11 (12.4%),
50 (56%) patients in group A, B, C, D, respectively.
Detailed clinical features in four difference groups are
presented in table 1. The result of all anti HCV test
were negative. Approximately 80% patients had
abdominal ultrasonography examinations and
the result were normal. Moreover, 8 patients had fatty
liver, and one patient had early chronic liver disease.
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Table 1. Clinical features, HBV DNA levels and HBsAg titers in four different groups 
Characteristic A B C D n = 16 n = 12 n = 11 n = 50  
Sex (male/female) 12/4 7/5 10/1 33/17 
Age (years) 31.3 ± 11.3 31 ± 11.2 40.2 ± 11.7 41.9 ± 9.4 
HBsAg level (IU/mL) 21.9 ± 7.9 23.2 ± 4.7 22.1 ± 6.0 22.8 ± 6.8 
HBV DNA (log IU/mL) 5.98 ± 1.22 6.84 ± 0.5 5.02 ± 1.46 3.68 ± 1.11 
ALT (median, range) 155 (82-2,116) 41 (17-62) 170 (82-2,301) 29 (11-73) 
Note: Kruskall-Wallis test: age p = 0.001; HBsAg level p = 0.95  
 
Pearson’s correlation test of HBsAg titers and HBV  
DNA level in HBeAg positive patients showed weak  
positive correlation but statistically, it was not  
significant (r = 0.28; p = 0.149). Similar result was  
also found in HBeAg negative patients (r = 0.22;  
p = 0.083) (figure 1).  
There were weak positive correlations in group A,  
C, and D but statistically, they were not significant  
(group A, r = 0.40; p = 0.12; group C, r = 0.28;  
p = 0.40; group D, r = 0.26; p = 0.07). In group B  
the correlation was negative (r = 0.40; p = 0.10)  
(figure 2). 
There were 15 cases in group A, which had serum 
HBV DNA level < 20,000 IU/mL and only one case  
had serum HBV DNA level < 20,000 IU/mL. The area  
under the ROC curve for baseline HBsAg level for  
predicting serum HBV DNA was 1.00 (95% CI = 
1.00-1.00; p = 0.107) (figure 3). At HBsAg cut off 
level 7.91 IU/mL, there were 100% sensitivity and 
100% specificity of serum HBV DNA level 
> 20,000 IU/mL. 
There were 12 cases B group with serum HBV  
DNA >  20,000 IU/mL, and zero case with serum HBV  
DNA level < 20,000 IU/mL. The area under  
the ROC curve of this group could not be performed.  
There were 9 cases in group C with serum HBV DNA  
< 2,000 IU/mL, 2 cases with serum HBV DNA level  
< 2,000 IU/mL. The area under the ROC curve for  
baseline HBsAg level for predicting  serum HBV DNA  
level was 0.67 (95% CI = 0.17-1.16; p = 0.48) (figure 
4). At HBsAg cut off level 13.51 IU/mL, the sensitivity  
and specificity for serum HBV DNA level  
> 2,000 IU/mL were 100% and 50% respectively.  
 There were 29 cases in group D with serum HBV  
DNA > 2,000 IU/mL and 21 cases with serum HBV  
DNA level < 2,000 IU/mL. The area under the ROC  
curve for baseline HBsAg level for predicting serum  
HBV DNA was 0.59 (95% CI = 0.43-0.75; p = 0.30)  
(figure 5). At HBsAg cut off level 21.38 IU/mL,  
the sensitivity and specificity for serum HBV DNA  
level > 2,000 IU/mL were 72% and 62% respectively. 
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Figure 1. Correlation HBsAg level and HBV DNA level among HBeAg 
positive and HBeAg negative patients. In group HBeAg positive  
r = 0.28; p = 0.149, and in group HBeAg negative r = 0.224; 
p = 0.083 
Figure 2. Correlation between HBsAg and serum HBV DNA levels 
among four different groups 
Figure 3. ROC curve analysis of HBsAg level with serum HBV DNA 
level > 20,000 mL in HBe positive and ALT level > 2 x ULN. The area 
under the ROC curve of HBsAg for predicting serum HBV DNA level 
was 1.00 (95% CI = 1.00-1.00; p = 0 .107) 
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When we stratified the subject into four groups,  
there were weak positive correlations between serum  
HBsAg level and HBV DNA level in group A, C and  
D patients; however, the correlation was not  
significant. Chan et al did not find any correlation  
between serum HBsAg level and HBV DNA level in  
HBeAg positive patients with high ALT level,2  which  
is similar to group A in our study. Lu et al who studied  
chronic hepatitis B in patients treated with antiviral  
therapies showed a significant correlation between  
serum HBV DNA levels and HBsAg levels (29 HBeAg  
negative patients and 57 HBeAg positive patients).  
They showed that the correlation still significant at 
Figure 4. ROC curve analysis of HBsAg level with serum HBV 
DNA level > 2,000 mL. The area under ROC curve for HBsAg level  
for   predicting serum HBV DNA level was 0.67 (95% CI = 0.17- 
1.16; p = 0.48) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. ROC curve analysis of level HBsAg with serum HBV DNA 
level < 2,000 mL in HBeAg negative group and ALT < 2 x ULN. 
The area under ROC curve for HBsAg level for predicting serum 
HBV DNA level was 0.59 (95% CI = 0.43-0.75; p = 0.30) 
 
DISCUSSION 
In our study there were weak positive correlation  
between serum HBsAg level and serum HBV DNA  
level in both HBeAg positive and HBeAg negative  
patients. However, it was statistically not significant.  
Chen et al, found a good correlation between HBsAg  
and HBV DNA levels in asymptomatic hepatitis B virus  
carriers. It was found both in HBeAg positive and  
HBeAg negative patients with normal ALT level.1  
Another study by Kohmoto et al, showed similar result  
in lamivudine-treated patients. In contrast,  
a retrospective study by Kuhn et al failed to find  
a correlation between HBsAg and HBV DNA level in  
untreated blood donors.5,6 Yoshikawa et al also found  
no significant correlation among asymptomatic blood  
donors in Japan.6 Galli et al found weak correlations  
(r = 0.177). The subject were 54 patients with HBeAg  
negative chronic inactive hepatitis B, 47 patients with  
HBeAg negative chronic hepatitis B and 12 patients  
with HBeAg positive chronic hepatitis B.6 
the end of follow-up period.7 
In group B patients, we found a weak negative  
correlation between HBsAg level and serum HBV  
DNA level, but statistically it was not significant. This  
group is similar to the HBeAg positive and normal  
ALT level subgroup (16 cases) in Chen’s study. They  
found that mean log HBsAg titer in this group were  
significantly higher than the other group which had  
HBeAg negative result with normal ALT and low or  
high HBV DNA level.2 Lu et al showed that the HBsAg  
serum level and intra hepatic cccDNA were  
significantly lower in HBeAg negative patients than  
HBeAg positive patients in chronic hepatitis B  
patients.7 Our study found no significant differences  
of HBsAg titers between group A, B, C an D. In group  
B, patients may be in low immune response stage  
(immune tolerance). Furthermore, the group B in our  
study and Chen’s study showed relatively younger age  
patients. 
In group C, there was a weak positive correlation  
but statistically it was not significant. This group is  
similar to a study conducted by Moucari, i.e. a group  
of patients with HBeAg negative result and high ALT  
level.6 They found that pre-treatment serum HBsAg  
levels were correlated significantly with baseline serum  
HBV DNA levels (Spearman rank correlation  
0.45).2 
Group D was similar to a subgroup in Chen’s study,  
the HBeAg-negative patient with normal ALT level.  
But, unlike the Chen’s study, we eliminated patients  
without countable HBV DNA levels (HBV DNA  
< 60 IU/mL).2 In this group, the age was significantly  
older than HBeAg-positive patients. In contrast,  
Mahtab et al who studied 88 chronic hepatitis B (CHB)  
patients aged between 8-22 years old, concluded that  
HBeAg negative CHB is an entity that can also be  
found in young population. In subgroup patients with  
HBeAg negative, they found 38.2% serum ALT level  
increased (cut-off level: 42 IU/L), 26.5% had high  
HBV DNA level (> 105 copies/mL), 17.6% had  
significant fibrosis, and necro-inflammation was seen  
in 56% patients.8  
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In group A, we found 100% sensitivity and
specificity in HBeAg-positive patient and high ALT
level, at HBsAg cut-off level of 7.91 IU/mL that could
predict serum HBV DNA level more than
20,000 IU/mL. Chen et al showed the best cut-off for
HBsAg in differentiating group asymptomatic
carriers  HBeAg positive with high HBV DNA levels
(> 2 x 107 copies/mL) with other asymptomatic
carrier HBeAg negative (HBV DNA level  < 103, 103
to 105 and > 105 copies/ml) was 15,000 IU/mL, with
both sensitivity and specificity 100 %.1
In group C, at HBsAg cut-off level of 13.51
IU/mL, the sensitivity and specificity for HBV DNA
serum level > 2,000 IU/mL were 100% and 50%
respectively. We did not find other study that has
similar characteristic to this group. In group D, there
were patients with HBeAg-negative result and ALT
level < 2 x UNL, and the baseline HBsAg level of
21.38 IU/mL was used for predicting serum HBV DNA
level > 2,000 IU/mL, with 72% sensitivity and 62%
specificity. Chen et al showed the best cut-off for
HBsAg in differentiating group asymptomatic carriers
HBeAg negative with low HBVDNA levels (< 103
copies/mL; PCR undetectable) to other asymptomatic
carriers HBeAg negative with higher HBV DNA level
(103 to 105 and > 105 copies/mL) was 1,600 IU/mL
with a sensitivity of 69.4% and specificity of 66.7%.1
We used reagent Vidas HBsAg ultra (Biomerieux,
Lyon, France), which may cause different results in
our study. Most authors now use the architect HBsAg
assay as utilized in studies conducted by Chen, Chan,
Lu and Moucari.1,2,3,9 Deguchi et al found that Architect
HBsAg QT (Abbot Japan Corp) is a reliable, sensitive
and specific assay for HBsAg detection and
quantification.10 Chen et al had mentioned in their
study that the old-generation assay could not measure
HBsAg titer accurately, and therefore, they used
the Abbot Architect HBsAg assay.11 However, Weber
et al evaluated Vidas HBsAg Ultra kit for detecting
HBsAg in 2006, which was compared to a well-
established test (AxSYM HBsAg v2, Abbot
diagnostics, Wiesbaden, Germany), and they
concluded that Vidas HBsAG Ultra is a highly
sensitive and specific tool and represents an
improvement for detecting of HBsAg in routine
diagnostic laboratories and the utilization of
the reagent in such laboratories is to determine
quantitative measurement of HBsAg titers.12,13
Other main limitations of this study include small
sample size and we did not conduct HBsAg and HBV
DNA simultaneously. Further study with consideration
of these limitations is needed to bring a more
conclusive result.
CONCLUSION
We found a weak-positive correlation between
HBsAg titers and HBV DNA levels in HBeAg-
positive patients, as well as in HBeAg-negative
patients. However, it was not significant. There were
weak positive correlations between HBsAg level and
HBV DNA serum level, for group A, C and D
patients, but again, they were not significant.
Moreover, in group B, the correlation was negative.
In group A, there was good accuracy to predict for
high serum HBV DNA level. In other  groups, HBsAg
was likely did not show good accuracy for serum
HBVDNA level.
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